Current Colorectal Cancer Reports最新文献_第3页

Treating Colorectal Cancer with Immunotherapy: Implications for Single versus Combination Therapy. 用免疫疗法治疗结直肠癌：单一疗法对联合疗法的影响。

Current Colorectal Cancer Reports Pub Date : 2020-10-01 Epub Date: 2020-08-20 DOI: 10.1007/s11888-020-00459-y

Sophiya Karki, Shahid Umar, Anup Kasi

{"title":"Treating Colorectal Cancer with Immunotherapy: Implications for Single versus Combination Therapy.","authors":"Sophiya Karki, Shahid Umar, Anup Kasi","doi":"10.1007/s11888-020-00459-y","DOIUrl":"10.1007/s11888-020-00459-y","url":null,"abstract":"Purpose of review: Colorectal cancer (CRC) is the second leading cause of cancer-associated deaths in the United States, with most metastatic cases subsequently turning refractory to standard chemotherapy. One of the promising current interventions is immunotherapy that relies on harnessing the body's immune mechanisms to kill the cancer cells. The aim of this review is to highlight the implications of single versus combination immunotherapy and identify the molecular features and mutations that enhance or deter responsiveness.Recent findings: Based on current findings, responsiveness is associated with deficiency of mismatch repair (dMMR) genes or presence of microsatellite instability (MSI-high), with high immunoscore and tumor-mutational burden contributing to better efficacy while BRAF mutation conferring no significant effect. Combination immunotherapy demonstrates better efficacy in treating MSI-high CRC compared to single agent immunotherapy or chemotherapy.Summary: Given improved responsiveness and overall survival, there is potential for immunotherapy to change the standard of care for metastatic CRC. Furthermore, stratifying the patients by their molecular features and mutation status is critical for establishing care.","PeriodicalId":45986,"journal":{"name":"Current Colorectal Cancer Reports","volume":"16 5","pages":"107-117"},"PeriodicalIF":0.0,"publicationDate":"2020-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594761/pdf/nihms-1622300.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38657442","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Molecular Pathogenesis and Classification of Colorectal Carcinoma. 结直肠癌的分子发病机制及分类。

Current Colorectal Cancer Reports Pub Date : 2020-09-01 Epub Date: 2020-08-15 DOI: 10.1007/s11888-020-00458-z

Anup Kasi, Shivani Handa, Sajjad Bhatti, Shahid Umar, Ajay Bansal, Weijing Sun

{"title":"Molecular Pathogenesis and Classification of Colorectal Carcinoma.","authors":"Anup Kasi, Shivani Handa, Sajjad Bhatti, Shahid Umar, Ajay Bansal, Weijing Sun","doi":"10.1007/s11888-020-00458-z","DOIUrl":"https://doi.org/10.1007/s11888-020-00458-z","url":null,"abstract":"Purpose of review: Molecular pathways in colorectal carcinogenesis involve several complex genetic and epigenetic modulations that cause normal colonic mucosa to metamorphose into a benign polyp and subsequently into a malignant tumor. Our purpose is to recapitulate historical and recent genomic research in order to augment the understanding of colorectal cancer pathogenesis.Recent findings: In 2015, the molecular classification for colorectal cancers was unified into one system with four distinct groups, also called as consensus molecular subtypes. This led to an enhanced understanding of molecular and immune signatures which has implications on predicting the clinical behavior as well as response to different therapeutic agents.Summary: In this review, we expound on the current literature as well as draw on our own experience to present the important molecular pathogenesis pathways, key genetic mutations, differences in pathogenesis of left versus right sided tumors as well as the molecular classification of colorectal cancers.","PeriodicalId":45986,"journal":{"name":"Current Colorectal Cancer Reports","volume":"16 5","pages":"97-106"},"PeriodicalIF":0.0,"publicationDate":"2020-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s11888-020-00458-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38456784","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 10

Non-surgical “Watch and Wait” Approach to Rectal Cancer 直肠癌症的非手术“观察和等待”方法

Current Colorectal Cancer Reports Pub Date : 2020-08-26 DOI: 10.1007/s11888-020-00460-5

Z. Ghiassi-Nejad, K. Goodman

引用次数: 0

Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials. 结直肠癌的免疫疗法：粪便移植和微生物群强化临床试验的潜力。

Current Colorectal Cancer Reports Pub Date : 2020-08-01 Epub Date: 2020-06-05 DOI: 10.1007/s11888-020-00456-1

Robin Park, Shahid Umar, Anup Kasi

{"title":"Immunotherapy in Colorectal Cancer: Potential of Fecal Transplant and Microbiota-augmented Clinical Trials.","authors":"Robin Park, Shahid Umar, Anup Kasi","doi":"10.1007/s11888-020-00456-1","DOIUrl":"10.1007/s11888-020-00456-1","url":null,"abstract":"Purpose of review: This review summarizes the role of the microbiome in colorectal cancer (CRC) in the setting of immunotherapy and emphasizes the potential of microbiota-influencing strategies with a focus on the use of fecal microbiota transplant (FMT).Recent findings: Observations from preclinical and clinical studies suggest that the human gut microbiome is implicated in the CRC carcinogenesis and is integral in determining the clinical response and toxicity to immunotherapy. Among the therapeutic methods devised to exploit the microbiome, FMT is the most direct method and is backed by the highest level of evidence of efficacy in nonneoplastic disease settings. Furthermore, a favorable microbiome has the potential to overcome immunotherapy resistance and ameliorate immune-related adverse events (irAEs). To this end, clinical trials are underway to evaluate the potential of FMT and microbiota-augmented methods in the setting of immunotherapy in CRC.Summary: Evidence from animal studies, retrospective studies, and smaller-scale prospective human studies have led to initiation of a number of microbiota-augmented clinical trials in CRC. Given the intimate relationship between the gut microbiota and the immune system as well as antitumor immune responses, potentiating immunotherapy and managing its toxicity are major areas of research in microbiota-augmented therapies in cancer. Therefore, evaluation of the patient microbiome as a routine part of clinical outcome analysis is warranted in future clinical trials.","PeriodicalId":45986,"journal":{"name":"Current Colorectal Cancer Reports","volume":"16 4","pages":"81-88"},"PeriodicalIF":0.0,"publicationDate":"2020-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325521/pdf/nihms-1601377.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"38105594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

On Hereditary Colorectal Cancer: What Is the Appropriate Surgical Technique? 关于遗传性结直肠癌:什么是合适的手术技术?

Current Colorectal Cancer Reports Pub Date : 2020-06-13 DOI: 10.1007/s11888-020-00457-0

Hector M. Ibarvo Gracia, Iris G. Saldaña Sanchez, A. Natour

引用次数: 0

Leisure-Time Physical Activity Versus Sedentary Behaviour in Relation to Colorectal Adenoma and Cancer: Are these Two Distinct Risk Factors? 休闲时间体育活动与久坐行为与结直肠腺瘤和癌症的关系:这是两个不同的危险因素吗?

Current Colorectal Cancer Reports Pub Date : 2020-06-09 DOI: 10.1007/s11888-020-00454-3

S. Mahmood, R. MacInnis, A. Karahalios, D. English, B. Lynch

引用次数: 1

Optimal Use of FOLFOXIRI Plus Bevacizumab as First-Line Systemic Treatment in Metastatic Colorectal Cancer FOLFOXIRI联合贝伐单抗一线系统治疗转移性结直肠癌癌症的最佳应用

Current Colorectal Cancer Reports Pub Date : 2020-06-04 DOI: 10.1007/s11888-020-00455-2

Jude Khatib, R. Kainthla

引用次数: 1

Current Options in the Management of Colorectal Cancer in Developing Countries: Central America Experience 当前发展中国家结直肠癌管理的选择:中美洲经验

Current Colorectal Cancer Reports Pub Date : 2020-05-11 DOI: 10.1007/s11888-020-00452-5

Anny Ochoa-Hernandez, Karen Giron, J. Meier, Ana Paulina Charchalac

引用次数: 1

Epidemiological Evidence for Dietary Sugars and Colorectal Cancer 膳食糖与结直肠癌的流行病学证据

Current Colorectal Cancer Reports Pub Date : 2020-05-06 DOI: 10.1007/s11888-020-00453-4

C. Yuan, E. Giovannucci

引用次数: 1

The Evolving Landscape of Neoadjuvant Radiation Therapy for Locally Advanced Rectal Cancer 局部晚期直肠癌新辅助放射治疗的发展前景

Current Colorectal Cancer Reports Pub Date : 2020-04-27 DOI: 10.1007/s11888-020-00451-6

S. Yoon, Percy Lee, A. Raldow

引用次数: 1